The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways. Besse L et al. Blood Cancer J. 2017 Jul 28;7(7):e589. doi: 10.1038/bcj.2017.69. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Hipp S et al. Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.219. [Epub ahead of print].…
A novel dual inhibitor of microtubule and Bruton’s Tyrosine Kinase inhibits survival of multiple myeloma and osteoclastogenesis. Pandey MK et al. Exp Hematol. 2017 Jun 21. pii: S0301-472X(17)30233-3. doi: 10.1016/j.exphem.2017.06.003. [Epub ahead of print]. Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma. Laganà A et al. Leukemia. 2017 Jun 23. doi: 10.1038/leu.2017.197. [Epub ahead of print]. Changes…
The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Thanendrarajan S et al. Haematologica. 2017 May 26. pii: haematol.2017.168872. doi: 10.3324/haematol.2017.168872. [Epub ahead of print]. Somatic mutation spectrum in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape compared to multiple myeloma. Mikulasova A et al. Haematologica. 2017 May 26.…
The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Mishima Y et al. Cell Rep. 2017 Apr 4;19(1):218-224. doi: 10.1016/j.celrep.2017.03.025. Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma. Dupéré-Richer D et al. Curr Opin Hematol. 2017 Apr 22. doi: 10.1097/MOH.0000000000000358. [Epub ahead of print]. Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple…
p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell. Tessoulin B et al. Blood Rev. 2017 Mar 4. pii: S0268-960X(16)30059-5. doi: 10.1016/j.blre.2017.03.001. [Epub ahead of print]. Mesenchymal stromal cells enhance the suppressive effects ofmyeloid-derived suppressor cells of multiple myeloma. Xu Y et al. Leuk Lymphoma. 2017 Mar 20:1-9. doi: 10.1080/10428194.2017.1298753. [Epub ahead of print]. Identification of…
Mutational landscape reflects the biological continuum of plasma cell dyscrasias. Rossi A et al. Blood Cancer J. 2017 Feb 24;7(2):e537. doi: 10.1038/bcj.2017.19. Ecto-5′ -Nucleotidase CD73 (NT5E), vitamin D receptor and FGF23 gene polymorphisms may play a role in the development of calcific uremic arteriolopathy in dialysis patients – Data from the German Calciphylaxis Registry. Rothe H et al. PLoS One. 2017…
Anti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell line. Durusu İZ et al. Leuk Res. 2017 Jan 16;55:33-40. doi: 10.1016/j.leukres.2017.01.019. [Epub ahead of print]. EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation. Adamik J et al. Mol Cancer Res. 2017 Jan 23. pii: molcanres.0242.2016. doi: 10.1158/1541-7786.MCR-16-0242-T. [Epub ahead of print].…
Proteomic profiling in plasma cell disorders: a feasibility study. Mailankody S et al. Leuk Lymphoma. 2016 Dec 2:1-3. [Epub ahead of print]. Tumor-associated macrophage-mediated survival of myeloma cells through STAT3 activation. De Beule N et al. J Pathol. 2016 Dec 15. doi: 10.1002/path.4860. [Epub ahead of print]. Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure. Dao K et…
Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression. Li N et al. Nat Commun. 2016 Nov 24;7:13656. doi: 10.1038/ncomms13656. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma. Jiménez C et al. J Mol Diagn. 2016 Nov 15. pii: S1525-1578(16)30186-6. doi: 10.1016/j.jmoldx.2016.08.004. [Epub ahead of print]. Exome copy number variation detection:…
Cytogenetics in the management of multiple myeloma: an update by the Groupe francophone de cytogénétique hématologique (GFCH). Daudignon A et al. Ann Biol Clin (Paris). 2016 Oct 1;74(5):588-595. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Sawyer JR et al. Leukemia. 2016 Oct 3. doi: 10.1038/leu.2016.253. [Epub ahead of print]. Knockdown of macrophage inhibitory cytokine-1 in RPMI-8226 human multiple myeloma cells inhibits osteoclastic…